Evidence map›Paper›PMID 34797962›Full record

Trial reportJournal of diabetes investigation2022

Preserved pharmacokinetics and pharmacodynamics of insulin degludec and liraglutide when administered as insulin degludec/liraglutide in a Chinese population.

Hongzhong Liu, Bin Luo, Xia Chen, Steen H Ingwersen, Ting Jia, Lisbeth Vestergård Jacobsen, Pei Hu

Open access · goldAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of diabetes investigation, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Trial
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 3 countries.

Hongzhong LiuClinical Pharmacology Research Center, Chinese Academy of Medical Sciences & Peking Union Medical College, Peking Union Medical College Hospital, Beijing, China.
Bin LuoNovo Nordisk China Pharmaceuticals Co. Ltd, Beijing, China.
Xia ChenClinical Pharmacology Research Center, Chinese Academy of Medical Sciences & Peking Union Medical College, Peking Union Medical College Hospital, Beijing, China.
Steen H IngwersenNovo Nordisk, Copenhagen, Denmark.
Ting JiaNovo Nordisk, Copenhagen, Denmark.
Lisbeth Vestergård JacobsenNovo Nordisk, Copenhagen, Denmark.
Pei HuClinical Pharmacology Research Center, Chinese Academy of Medical Sciences & Peking Union Medical College, Peking Union Medical College Hospital, Beijing, China.ORCID https://orcid.org/0000-0002-7727-4902
Chinese Academy of Medical Sciences & Peking Union Medical College · CNNovo Nordisk (Denmark) · DKNovo Nordisk (Switzerland) · CH

Funding

Novo Nordisk
6 · The paper itself

Abstract

We report the findings of a single-dose, randomized, three-period cross-over, clinical trial in healthy Chinese individuals (n = 24) comparing the pharmacokinetics of insulin degludec/liraglutide (IDegLira) with its individual components. Furthermore, we report a population pharmacokinetic analysis of a 26-week, phase III, treat-to-target, randomized trial of 720 Chinese individuals with type 2 diabetes. Participants were randomized to IDegLira, degludec or liraglutide, all once daily with metformin. The pharmacokinetic profiles of IDegLira were similar to its individual components. Dose proportionality was indicated for both IDegLira components. Although there were no relevant covariate effects on degludec exposure, liraglutide exposure was inversely correlated with bodyweight. In conclusion, for the Chinese population, the pharmacokinetics of the fixed-ratio combination IDegLira is similar to that of its individual components.

Indexed as

Diabetes Mellitus, Type 2LiraglutideBlood GlucoseChinaDrug CombinationsGlycated HemoglobinHumansHypoglycemic AgentsInsulin, Long-ActingBlood GlucoseDrug CombinationsGlycated HemoglobinHypoglycemic Agentsinsulin degludecInsulin, Long-ActingLiraglutideIDegLiraPharmacokineticsType 2 diabetes mellitus

Identifiers

PMID34797962
PMCPMC9017614
OpenAlexW3213131211

What OpenQuestion holds

Texttitle and abstract
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.